论文部分内容阅读
目的为观察重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)治疗恶性肿瘤介入化疗所致白细胞减少症的临床疗效。方法采用同期住院接受介入化疗发生白细胞减少症患者共36人(外周白细胞计数小于3×10~9/L),在出现白细胞减少的第1~3天内肌注rhGM-CSF100μg,第5天行血常规检查,如白细胞计数高于正常值,则停用rhGM-CSF,如还低于正常值,则在第6-8天再肌注100μg,第10天复查血常规。结果本组36例用药后显效率58.2%(21/36),有效率为83.3%(10/36)。共有30例治疗后白细胞总数、中性粒细胞绝对数和百分数的平均值均高于治疗前(P <0.01)。本组未见明显副反应。结论rhGM-CSF在恶性肿瘤介入化疗所致白细胞减少症治疗中,采用较文献偏低剂量完全能够维持白细胞的正常水平,且用药安全,无明显毒副作用。
Objective To observe the clinical efficacy of recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) in the treatment of leukopenia caused by interventional chemotherapy for malignant tumors. Methods Thirty-six leukopenia patients were enrolled in the same period of hospitalization for interventional chemotherapy (peripheral white blood cell count was less than 3×10 9 /L), intramuscular injection of rhGM-CSF 100 μg in the first 3 days of leukopenia, and blood was given on the fifth day. Routine examination, such as the white blood cell count is higher than normal, then disable rhGM-CSF, if it is still lower than the normal value, then intramuscular injection of 100μg on the 6th-8th day, recheck blood routine on the 10th day. Results The effective rate was 58.2% (21/36) in 36 cases of this group, and the effective rate was 83.3% (10/36). The total number of white blood cells and the absolute number and percentage of neutrophils after treatment were higher than those before treatment (P < 0.01). No obvious side effects were seen in this group. Conclusion rhGM-CSF can be used to treat leukopenia caused by interventional chemotherapy in malignant tumors. It can maintain the normal level of white blood cells at a lower dose than the literature. It is safe and has no obvious side effects.